Detectable concentrations of Fas ligand in cerebrospinal fluid after severe head injury

Journal of Neuroimmunology

Volumn 80, Issue 1-2, 1997, Pages 93-96

  Ertel, Wolfgang ^a   Keel, Marius ^a   Stocker, Reto ^a   Imhof, Hans Georg ^a   Leist, Marcel ^b   Steckholzer, Ursula ^a   Tanaka, Masato ^c   Trentz, Otmar ^a   Nagata, Shigekazu ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF KONSTANZ   (Germany)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Apoptosis; Brain oedema; Cerebrospinal fluid; Fas antigen; Fas ligand; Head injury

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADULT; APOPTOSIS; ARTICLE; BRAIN EDEMA; CEREBROSPINAL FLUID; CLINICAL ARTICLE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAD INJURY; HUMAN; INJURY SCALE; PRIORITY JOURNAL; SCORING SYSTEM;

ADULT; ANTIGENS, CD95; APOPTOSIS; BLOOD-BRAIN BARRIER; BRAIN EDEMA; BRAIN INJURIES; CEREBROVASCULAR CIRCULATION; FAS LIGAND PROTEIN; HUMANS; INTRACRANIAL PRESSURE; LIGANDS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; SOLUBILITY;

EID: 0031457493     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00139-2     Document Type: Article

References (21)

1. Cheng J., Zhou T., Liu C., Shapiro J.P., Brauer M.J., Kiefer M.C., Barr P.J., Mountz J.D. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 263:1994;1759-1762.
2. Dhein J., Walczak H., Bäumler C., Debatin K.M., Krammer P.H. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature (Lond.). 373:1995;438-441.
3. Dowling P., Shang G., Raval S., Menonna J., Cook S., Husar W. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J. Exp. Med. 184:1996;1513-1518.
4. Fabry Z., Raine C.S., Hart N. Nervous tissue as an immune compartment: The dialect of the immune response in the CNS. Immunol. Today. 15:1994;218-224.
5. French L.E., Hahne M., Viard I., Radlgruber G., Zanone R., Becker K., Müller C., Tschopp J. Fas and Fas Ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J. Cell. Biol. 133:1996;335-343.
6. Galle P.R., Hofmann W.J., Walczak H., Schaller H., Otto G., Stremmel W., Krammer P.H., Runkel L. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med. 182:1995;1223-1230.
7. Gennarelli T.A., Champion H.R., Copes W.S., Sacco W.J. Comparison of mortality, morbidity, and severity of 59713 head injured patients with 114447 patients with extracranial injuries. J. Trauma. 37:1994;962-968.
8. Kobayashi N., Hamamoto Y., Yamamoto N., Ishii A., Yonehara M., Yonehara S. Anti-Fas monoclonal antibody is cytocidal to human immunodeficiency virus-infected cells without augmenting viral replication. Proc. Natl. Acad. Sci. USA. 87:1990;9620-9624.
9. Lau H.T., Yu M., Fontana A., Stoeckert C.J. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science. 273:1996;109-112.
10. Matsuyama T., Hata R., Tagaya M., Yamamoto Y., Nakajima T., Jun-ichi F., Wanaka A., Sugita M. Fas antigen mRNA induction in postischemic murine brain. Brain Res. 657:1994;342-346.
11. Nagata S., Golstein P. The Fas death factor. Science. 267:1995;1449-1456.
12. Nagata S., Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol. Today. 16:1995;39-43.
13. Ogasawara J., Watanabe-Fukunaga R., Adachi M., Matsuzawa A., Kasugai T., Kitamura Y., Itoh N., Suda T., Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature (Lond). 364:1993;806-809.
14. Reiber H., Felgenhauer K. Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. Clin. Chim. Acta. 163:1987;319-328.
15. Saas P., Walker P.R., Hahne M., Quiquerez A.L., Schnuriger V., Perrin G., French L., Van Meir E.G., de Tribolet N., Tschopp J., Dietrich P.Y. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain? J. Clin. Invest. 99:1997;1173-1178.
16. Saul T.G., Ducker T.B. Effect of intracranial pressure monitoring and aggressive treatment on mortality in severe head injury. J. Neurosurg. 56:1982;498-503.
17. Sosin D.M., Sacks J.J., Smith S.M. Head injury-associated deaths in the United States from 1979-1986. JAMA. 262:1989;2251-2255.
18. Stocker R., Bernays R., Kossmann T., Imhof H.G. Monitoring and treatment of acute head injury. Update Intens. Care. Emerg. Med. 22:1995;196-210.
19. Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1993;1169-1178.
20. Suda T., Okazaki T., Naito Y., Yokota T., Arai N., Ozaki S., Nakao K., Nagata S. Expression of the Fas ligand in cells of T cell lineage. J. Immunol. 154:1995;3806-3813.
21. Tanaka M., Suda T., Haze K., Nakamura N., Sato K., Kimura F., Motoyoshi K., Mizuki M., Tagawa S., Ohga S., Hatake K., Drummond A.H., Nagata S. Fas ligand in human serum. Nat. Med. 2:1996;317-322.